State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

State Street Corp lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 7.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 772,825 shares of the company’s stock after buying an additional 52,966 shares during the quarter. State Street Corp owned about 1.47% of Zevra Therapeutics worth $5,363,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vestal Point Capital LP bought a new position in Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Sanctuary Advisors LLC bought a new position in shares of Zevra Therapeutics in the 2nd quarter worth $474,000. Propel Bio Management LLC acquired a new stake in shares of Zevra Therapeutics during the third quarter worth $1,248,000. Simplify Asset Management Inc. bought a new stake in Zevra Therapeutics in the third quarter valued at about $833,000. Finally, FMR LLC lifted its stake in Zevra Therapeutics by 282,687.5% in the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after buying an additional 2,312,384 shares during the period. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock opened at $8.39 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a market cap of $447.82 million, a price-to-earnings ratio of -4.26 and a beta of 1.97. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The stock’s 50-day moving average is $8.74 and its 200-day moving average is $7.39.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the business earned ($0.40) earnings per share. Equities analysts predict that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. JMP Securities began coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price for the company. Maxim Group boosted their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Roth Mkm increased their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.